ESMO 2018 | Is RANGE providing the targeted therapies needed for urothelial cancer?
Get great new content delivered to your inboxSign up
Comparison of investigator-initiated and industry-initiated trials by Dr Sridhar
Enfortumab vedotin as treatment for urothelial carcinomas
Issues surrounding patient-centered outcomes in the genitourinary field
The evolving first-line treatment landscape for advanced RCC
Key bladder cancer updates from ASCO GU 2019
More from Thomas Powles